Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
BUSINESS
Choseido Contract Manufactured Cephem Antibiotics for 8 Firms
Choseido Pharmaceutical contract manufactured cephem antibiotics for eight generic makers at its scandal-hit Kawauchi Plant, which is now suspended, including Sawai Pharmaceutical and Towa Pharmaceutical, it has been learned. On June 12, Choseido released a list of customer companies for…
To read the full story
Related Article
- Academic Society Frets Availability of 1st-Gen Oral Cephems amid Choseido Halt
June 24, 2024
- Concerns Grow over Supply of Cephem Antibiotics after Choseido Plant Halt
June 19, 2024
- Sawai Recalls Antibiotic Cefdinir Manufactured by Choseido, 4 Other APIs
May 27, 2024
- Choseido Violates GMP Once Again with Cefdinir, More Cases Being Probed
May 27, 2024
BUSINESS
- Lilly Japan Halts Manufacturing of Strattera over Nitrosamine Impurities
November 14, 2024
- Daiichi Sankyo Replaces FDA Lung Cancer Filing for TROP2-Directed ADC
November 13, 2024
- Pfizer’s Antibiotic Zavicefta Now Available in Japan
November 13, 2024
- Terumo Rolls Out Anapeine Generics after Expedited Listing
November 13, 2024
- Moderna Sees CMV, EBV Vaccines as “Significant Assets”: Medical Affairs Chief
November 12, 2024
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…